Human herpes virus 8 (HHV-8) has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologs to several cellular regulatory genes into its genome. One of the important pirated genes encoded by the ORF K9 reading frame is a viral homolog of the interferon regulatory factors (IRF), a family of cellular transcription proteins that regulates expression of genes involved in pathogen response, immune modulation and cell proliferation. vIRF-1 has been shown to downregulate the interferon-and IRF-mediated transcriptional activation of ISG and murine IFNA4 gene promoters. In this study we demonstrate that vIRF-1 eciently inhibited virus-induced expression of endogenous interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes. Co-expression analysis revealed that vIRF-1 selectively blocked IRF-3 but not IRF-7-mediated transactivation. vIRF-1 was able to bind to both IRF-3 and IRF-7 in vivo as detected by coimmunoprecipitation analysis, but did not aect IRF-3 dimerization, nuclear translocation and DNA binding activity. Rather, vIRF-1 interacted with the CBP/p300 coactivators and eciently inhibited the formation of transcriptionally competent IRF-3-CBP/p300 complexes. These results illustrate that vIRF-1 is able to block the early stages of the IFN response to virus infection by interfering with the activation of IRF-3 responsive, immediate early IFN genes. Oncogene (2001) 20, 800 ± 811.
Introduction
Human herpesvirus type 8 (HHV-8/KSHV) is recognized as the essential infectious agent responsible for Kaposi's sarcoma, body cavity B cell lymphoma and some forms of Castelman's disease, an atypical B cell lymphoproliferative disorder (Chang et al., 1994; Moore et al., 1996; Soulier et al., 1995) . Early studies also suggested that HHV-8 infection frequently occurred in patients with multiple myeloma (reviewed in Vescio and Berenson, 1999) . At the cellular level, viral DNA and RNA sequences have been identi®ed in the majority of HHV-8 infected lymphocytes as well as endothelial cells which are considered to be among the primary targets for HHV-8 induced pathogenesis. Although some cells are latently infected, a subpopulation of these target cells are able to support viral growth. Because HHV-8 is a lymphotropic herpesvirus with a natural B cell target, reactivation of the virus from the lymphoid reservoir appears to be required for the spread of virus to the endothelium during the early stages of pathogenesis.
Unlike other human tumor viruses which have evolved multifunctional viral oncogenes that control viral replication and oncogenesis, HHV-8 has developed unique mechanisms for altering cellular proliferative and apoptotic control pathways by incorporating viral homologs to several cellular regulatory genes into their genome (reviewed in Sarid et al., 1999) . These HHV-8 encoded cellular homologs include: cytokine and cytokine signal transduction gene products , a cell cycle regulator (v-cyclin D) , and inhibitors of apoptosis (Sarid et al., 1999) . In general, expression of these proteins permits the manipulation of the local environment for ecient viral replication and evasion of the immune response and also may contribute to host proliferation and cell transformation.
One of the important pirated genes encoded by the ORF K9 reading frame represents a viral homolog of the interferon regulatory factors (IRF), a family of cellular transcription proteins that regulates expression of genes involved in pathogen response, immune modulation and cell proliferation (reviewed in Mamane et al., 1999; Nguyen et al., 1997) . HHV-8 encodes four IRF homologues termed vIRFs which inhibit responses to type I and II interferons and block IRF-1 mediated transcription. vIRF-1, a 449 amino acid protein, does not compete with IRF-1 for DNA binding, but seems to inhibit interferon and IRF-1 through an unde®ned mechanism Zimring et al., 1998) . Several studies demonstrated that vIRF-1 eectively inhibited interferon (IFN) signaling (Gao, 1997; Zimring et al., 1998) , suggesting a novel mechanism by which HHV-8 could escape the host immune response. Similar to the cellular IRF-2 protooncogene, vIRF-1 also prevented IFN induction of the cell cycle inhibitor p21 waf and induced cellular transformation. Furthermore, expression of vIRF also activated HHV-8 genes such as the v-IL-6 and inhibited radiation and adriamycin-induced apoptosis in HHV-8 infected cells (Sarid et al., 1999) . These novel viral strategies aimed at blocking IFN antiviral activity and induction of programmed cell death may also substantially contribute to early events leading to cellular transformation. Recent studies also demonstrated that in virus-infected cells, vIRF-1 speci®cally repressed the transcription of the murine IFNA4 gene promoter (Burysek et al., 1999) . A GST pull-down assay demonstrated that vIRF-1 interacted with IRF-1 and co-activator p300 (Burysek et al., 1999) . Despite the initial characterization of the role of vIRF in HHV-8 induced pathogenesis and oncogenesis, the mechanisms involved in the regulation of gene expression and tumorigenesis by vIRF remain to be elucidated.
Recent studies have demonstrated that IRF-3 and IRF-7 play an important role in the virus-induced type I interferon gene activation following virus infection (Au et al., 1998; Lin et al., 1998 Lin et al., , 1999a Mamane et al., 1999; MarieÂ et al., 1998; Sato et al., 1998; Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al., 1998) . Virus-induced C-terminal phosphorlyation of IRF-3 promotes cytoplasmic to nuclear translocation, DNA binding, association with CBP/p300 histone acetyltransferases and transactivation of downstream target genes. Type 1 IFNs can be subdivided into two groups: (1) immediate-early genes such as IFNb and human IFNa1 are activated in response to virus by a protein synthesis independent pathway (via activation of IRF-3 and other transcription factors); and (2) delayed-type genes which include the other IFNa subtypes whose expression is dependent in part on de novo synthesis of IRF-7. Dierential activation of type 1 IFN genes is in part regulated by the distinct DNA binding speci®cities of these factors and also by the ability to interact with histone acetyltransferase coactivators. Whereas IRF-3 possesses a restricted DNA binding site speci®city and interacts with CBP/p300 coactivators, IRF-7 has a broader DNA binding speci®city that contributes to its capacity to stimulate delayed type IFN gene expression .
In this study we examined whether vIRF-1 can repress IRF-3 or IRF-7-mediated interferon and chemokine gene activation. Our results indicate that vIRF-1 eciently inhibits the virus-induced expression of endogenous interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes. Co-expression analysis demonstrated that vIRF-1 selectively blocked IRF-3-but not IRF-7-mediated transactivation. Repression of IRF-3-mediated transcription by vIRF-1 correlates with the capacity of vIRF-1 to compete with IRF-3 in vivo for recruitment of the CBP/p300 coactivators.
Results

vIRF-1 represses virus-mediated interferon and chemokine gene activation
In transient expression assays, vIRF-1 has been shown to repress virus-, IRF-or IFN-stimulated transcriptional activity of ISRE-containing promoters (Burysek et al., 1999; Gao, 1997; Li et al., 1998; Zimring et al., 1998) . To determine whether the vIRF-1 could repress the virus-stimulated expression of endogenous interferon and chemokine genes, human embryonic kidney (293) cells that stably express vIRF-1 were generated ( Figure 1a) . The 293/vIRF-1 and the control 293/ pcDNA3 cells were infected with Sendai virus and an RNase protection assay was used to examine the expression of multiple human cytokine-chemokine RNAs derived from these cells. As shown in Figure  1b , IFNB, CC chemokine RANTES and CXC Figure 1 vIRF-1 represses Sendai virus-induced RNA expression of IFNB, RANTES and IP-10 genes. (a) Whole cell extracts (20 mg) prepared from uninfected or Sendai virus infected pcDNA3 and vIRF-1 human embryonic kidney (293) cells were subjected to SDS ± PAGE and probed with anti-myc antibody 9E10 to detect vIRF-1 expression. (b) The pcDNA3 and vIRF-1 cells were either untreated or infected with Sendai virus (80 HAU/ ml) for 8 h. Total RNA was isolated from each sample and analysed by RNase protection analysis (RPA) using the hCK3 and hCK5 kits (Pharmingen) as described in Materials and methods
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Inhibition of IRF-3 transactivation by vIRF-1 R Lin et al chemokine IP-10 genes were highly expressed in virusinfected 293/pcDNA3 cells ( Figure 1 , lane 2), whereas in virus-infected vIRF-1 expressing cells, IFNB and IP-10 were completely inhibited and the RANTES mRNA levels were reduced at least 20-fold (Figure 1b, lane 4) . The expression of these cytokine-chemokine genes was not detected in uninfected cells (Figure 1b, lanes 1 and  3) and as a relative measure of speci®city, the level of TGFb RNA was not altered by vIRF-1 expression (Figure 1b) . These results demonstrated that vIRF-1 expression dramatically reduced virus-induced IFN and chemokine mRNA production.
vIRF-1 represses IRF-3-but not IRF-7-mediated transactivation
Since dominant negative forms of IRF-3 and IRF-7 have been shown to interfere with IFN, RANTES and IP-10 RNA production (Au et al., 1998; Genin et al., 2000; Lin et al., 1998 Lin et al., , 1999a MarieÂ et al., 1998; Sato et al., 1998; Yoneyama et al., 1998) , we next determined whether vIRF-1 repressed IRF-3-or IRF-7-mediated transcriptional activity. A transient expression assay was performed using the RANTES promoter construct together with IRF-3, IRF-7 and/or vIRF-1 expression plasmids. In uninfected cells, the RANTES promoter had a low basal activity that was decreased slightly with vIRF-1 expression (Figure 2a ). Virus infection resulted in a 110-fold induction of RANTES promoter activity, while co-expression of vIRF-1 reduced virus induction of RANTES by ®vefold (Figure 2a) . Cotransfection of the constitutively active form of IRF-3 [IRF-3(5D)] activated RANTES promoter up to 210-fold in uninfected cells and again expression of vIRF-1 reduced the IRF-3(5D)-mediated transactivation more than 10-fold (Figure 2a ). However, cotransfection of vIRF-1 had essentially no eect on the inducible expression of RANTES promoter by wildtype IRF-7 or by a constitutively active form of IRF-7 ( Figure 2a ). As shown in Figure 2b , the ISRE motif in the RANTES promoter was required for vIRF-1-mediated repression, since cotransfection of vIRF-1 had essentially no eect on the expression of the ISREmutated RANTES promoter. The repressive potential of vIRF-1 was also analysed using the IFNB-directed reporter constructs and similar inhibitory eects were observed (Figure 2c ). Equivalent results were also obtained using the human IFNA1 promoter (data not shown), indicating that IRF-3 but not IRF-7 was targeted by the inhibitory eect of vIRF-1.
vIRF-1 associates with IRF-3 and IRF-7
To examine the possibility that vIRF-1 associated with IRF-3, coimmunoprecipitation-immunoblot experiments were performed using 293 cells cotransfected with Flag-tagged vIRF-1 and myc-tagged IRF-3. After immunoprecipitation of myc-tagged IRF-3 or IRF-3(5D) from whole cell extracts with anti-myc antibody (Lin et al., 1999b) , immunoblot analysis indicated that vIRF-1 coprecipitated with myc-tagged IRF-3 and IRF-3(5D) (Figure 3a , lanes 3 and 4) but not with control mouse serum (data not shown). Interaction between IRF-3 and vIRF-1 required part of the IAD domain, since vIRF-1 coimmunopreciptated with IRF-3 (1 ± 394), IRF-3 (1 ± 357) and IRF-3 (1 ± 240) proteins which contained all or part of the IAD domain ( Figure  3a , lanes 5 ± 7), but did not coimmunoprecipitate with IRF-3 (1 ± 197) which lacked the C-terminal IAD domain ( Figure 3a , lane 8). To localize the region within the vIRF-1 that interacted with the IAD domain of IRF-3, dierent vIRF-1 deletions were tested for interaction with myc-IRF-3(5D). As shown in Figure 3b , the N-terminal region of vIRF-1 associated with IRF-3, since vIRF-1 (1 ± 160), vIRF-1 (1 ± 310) and full length vIRF-1 were coprecipitated with myc-IRF-3(5D) (Figure 3b , lanes 1 ± 3), whereas the C-terminal portion of vIRF-1 (aa 156 ± 449) did not interact with IRF-3(5D). Both wildtype and constitutively active forms of IRF-7 are also associated with vIRF-1 ( Figure 3a , lanes 1 and 2).
Since the IAD domain is required for the dimerization of IRF-3(5D) (Lin et al., 1999b) and vIRF-1 also interacted with IAD domain of IRF-3, we next examined whether vIRF-1 was able to block the homodimerization of IRF-3(5D). 293 cell were cotransfected with myc-tagged IRF-3(5D), Flag-tagged IRF-3(5D) and Flag-tagged vIRF-1. After immunoprecipitation with anti-myc antibody 9E10, the immunoprecipitates were analysed with anti-Flag antibody M2. The interaction between Flag-tagged IRF-3(5D) and myc-tagged IRF-3(5D) (Figure 3c , lane 1) was much stronger than the interaction between Flag-tagged vIRF-1 and myc-tagged IRF-3(5D) (Figure 3c , lane 3). In fact, vIRF-1 expression did not signi®cantly aect the dimerization of IRF-3(5D) (Figure 3c , compare lanes 1 and 2). Furthermore, analysis of IRF-3 cytoplasmic to nuclear translocation using GFP-linked IRF-3 indicated that vIRF-1 did not aect virus-induced subcellular translocation of IRF-3 (data not shown). Together, these results indicate that dimerization and nuclear translocation were not aected by vIRF-1 expression and suggested that other mechanisms are involved in the inhibition of IRF-3-mediated transactivation by vIRF-1.
vIRF-1 blocks the interaction between IRF-3 and CBP/P300 coactivators
The histone acetyltransferase coactivators CBP and p300 associate with the C-terminally phosphorylated form of IRF-3 Yoneyama et al., 1998; Wathelet et al., 1998; Weaver et al., 1998) but not with IRF-7 . Since vIRF-1 was shown to interact with the p300 coactivator in vitro (Burysek et al., 1999) and vIRF-1 repressed IRF-3-but not IRF-7-mediated transactivation, we next examined whether vIRF-1 could interact with CBP/p300 coactivators in vivo and block the association between IRF-3 and CBP/p300 coactivators. Flag-tagged IRF-3(5D) and increasing amounts of myc-tagged vIRF-1 were transiently transfected into 293 cells. After immuno-precipitation of endogenous CBP from whole cell extracts with anti-CBP antibody A22, immunoblot analysis with anti-myc antibody 9E10 revealed that vIRF-1 coprecipitated with CBP ( Figure 4a , lanes 2 ± 4, third panel) but not with preimmune serum (data not shown). Immunoblot analysis of the same membrane CBP contains several distinct domains that interact with dierent transcription factors, designated CBP1 Figure 3 vIRF-1 interacts with IRF-3 and IRF-7. 293 cells were transfected with Flag-tagged vIRF-1 and myc-tagged wildtype or mutated forms of IRF-3 or IRF-7 expressing plasmids (a), myc-tagged IRF-3(5D) and Flag-tagged full length or deleted forms of vIRF-1 expressing plasmids (b), and myc-tagged IRF-3(5D), Flag-tagged IRF-3(5D) and/or vIRF-1 as indicated above the lanes. Whole cell extracts (300 mg) were immunoprecipitated with anti-myc antibody 9E10. Immunoprecipitated complexes (upper panel) or 20 mg of whole cell extracts (middle panel) were run on 10% SDS ± PAGE and subsequently probed with anti-Flag antibody M2 and the same membranes of the upper panel were reprobed with anti-myc antibody 9E10 (lower panel) (aa 399 ± 790), CBP2 (aa 1677 ± 1897), and CBP3 (aa 1992 ± 2441) (Gu et al., 1997; Lin et al., 1998) . To determine which domain of CBP interacts with vIRF-1, 293 cells were cotransfected with the three myc-tagged CBP expression plasmids and the Flag-tagged vIRF-1 expression plasmid. At 24 h after transfection, whole cell extracts were prepared, coimmunoprecipitated with anti-myc antibody 9E10 and then immunoblotted for vIRF-1 with anti-Flag antibody M2. The results demonstrated Flag-vIRF-1 associated with the Cterminal portion of CBP (CBP3) (Figure 4b, lane 3) . No interaction was detected with CBP1 or CBP2 (Figure 4b, lanes 1 and 2) . Immunoblot analysis of the whole cell extracts (data not shown) and the immunoprecipitates revealed that all three myc-tagged CBP proteins were eciently expressed and immunoprecipitated ( Figure 4b , middle panel). These results demonstrate that vIRF-1 binds speci®cally to the Cterminal domain of CBP, the same region that interacts with IRF-3.
Following the overexpression studies, the virusinduced interaction of endogenous IRF-3 and CBP coactivator was also analysed in control pcDNA3 and vIRF-1 cell lines. After Sendai virus infection, CBP was immunoprecipitated with anti-CBP antibody A22 and the immunoprecipitate was analysed for the presence of IRF-3; as shown previously , endogenous IRF-3 coimmunoprecipitated with CBP in Sendai virus-infected cells (Figure 5a , lanes 2 ± 4, second panel) but not in uninfected cells (Figure 5a , lane 1). However, in virus-infected cells expressing vIRF-1, the amount of IRF-3 coimmunoprecipitated together with CBP was dramatically decreased by 5 ± 10-fold (Figure 5a , lanes 6 ± 8, second panel). The weak interaction between IRF-3 and CBP in Sendai virusinfected vIRF-1 expressing cells was not due to the eect of vIRF-1 on IRF-3 phosphorylation, since the virus-induced IRF-3 phosphorylation was detectable in both pcDNA3 and vIRF-1 cells ( Figure 5a , lanes 2 ± 4 and 6 ± 8, lower panel).
Co-immunopreciptation was also performed with anti-p300 antibody N15. Similar to the results with CBP, the interaction between p300 and IRF-3 was detected in virus infected cells (Figure 5b , lanes 2 and 3, second panel) but not in uninfected cells (Figure 5b , lane 1, second panel). The expression of vIRF-1 also eciently blocked the virus-induced IRF-3/p300 interaction (Figure 5b , lanes 5 and 6, second panel). Since vIRF-1 strongly associated with CBP ( Figure 5a , lanes 5 ± 8) and p300 (Figure 5b , lanes 4 ± 6) both in virusinfected or uninfected cells, vIRF-1 might compete with IRF-3 for binding to CBP/p300 coactivators.
vIRF-1 blocks IRF-3-CBP-DNA complex formation but not IRF-3-DNA complex formation
To further support vIRF-1 inhibition of IRF-3-mediated gene activation with speci®c protein DNA interactions, IRF-3(5D) and/or vIRF-1 were transiently expressed in 293 cells and the DNA binding capacity of IRF-3(5D) was determined by EMSA using a PRDIII-PRDI oligonucleotide from the IFNB gene ( Figure 6 ) or an ISRE oligonucleotide from the ISG15 gene (data not shown). In IRF-3(5D)-expressing cells, a (Figure 6 , lanes 6 and 7), as previously described (Lin et al., 1999b) . Strikingly, this slower migrating IRF-3-CBP-DNA complex disappeared when vIRF-1 was coexpressed with IRF-3(5D) (Figure 6 , lane 3) and was replaced by a faster migrating protein-DNA complex ( Figure 6, lane 3) . This faster migrating protein-DNA complex contained IRF-3 as con®rmed by supershift analysis (Figure 6 , lane 9) but did not contain CBP, since the addition of the A22 antibody did not aect complex formation (Figure 6 , lane 10). Competition with excess ISRE elements from the RANTES promoters successfully depleted the binding of the complex (Figure 6, lanes 4 and 11) , whereas mutated RANTES ISRE failed to compete for IRF-3(5D) binding activity (Figure 6, lanes 5 and 8) . As demonstrated previously Zimring et al., 1998) , vIRF-1 alone did not bind to the PRDIII-PRDI site ( Figure 6, lane 1) . Clearly, vIRF-1 was able to block the formation of the IRF-3-CBP/p300-DNA complex but did not aect the independent DNA binding activity of IRF-3.
Full length vIRF-1 is required for the inhibition of IRF-3-CBP/P300 interaction and IRF-3-mediated transactivation Next, we sought to localize the region within vIRF-1 that interacted with CBP and p300 coactivators. Dierent Flag-tagged vIRF-1 deletions were transfected into 293 cells and tested for CBP interaction. Initial experiments revealed that full length and deleted forms of vIRF-1, including aa 1 ± 310, aa 1 ± 160 and aa 159 ± 449 all associated independently with CBP (data not shown). Next, the eects of these vIRF-1 deletions on IRF-3-CBP interaction were investigated by coimmunoprecipitation using 293 cells cotransfected with Flag-tagged IRF-3(5D) and various vIRF-1 deletions. As shown in Figure 7a , in the absence of P-labelled probe corresponds to the PRDI-PRDIII (5'-GAAAACTGAAAGGGA-GAAGTGAAAGTG-3') motif of IFNB promoter. Anti-CBP antibody A22 and anti-IRF-3 antibody were added as indicated to demonstrate the presence of CBP and IRF-3 in the protein-DNA complex, indicated by the arrows. For oligonucleotide competition, a 500-fold molar excess of unlabeled wildtype or mutated oligonucleotide corresponding to the ISRE region of the RANTES promoter (wt: 5'-CTATTT-CAGTTTTCTTTTCCGTTTTGTG-3', mut: 5'-CTATTTCAG-TAAACTAAACCGTTTTGTG-3') was added as indicated above the lanes vIRF-1 coexpression, IRF-3(5D) strongly co-precipitated with CBP ( Figure 7a, lane 1) . Cotransfection of full length vIRF-1 signi®cantly reduced the amount of IRF-3(5D) bound to CBP (Figure 7a, lane 2) . The expression of the other truncated forms of vIRF-1 (aa 1 ± 310, aa 1 ± 160 and aa 151 ± 449) did not signi®-cantly aect IRF-3(5D)-CBP interaction (Figure 7a , lanes 3 ± 5): furthermore, the presence of IRF-3(5D) blocked the interaction between CBP and vIRF-1 (aa 1 ± 310) or vIRF-1 (aa 156 ± 449) (Figure 7a, lanes 3  and 5) . These results demonstrate that vIRF-1 competes with the active form of IRF-3 for binding to CBP coactivator.
Finally, to complement the protein-interaction data, the eects of various vIRF-1 deletions on virus-induced or IRF-3(5D)-mediated gene expression were examined by reporter gene assay using the RANTES promoter. In uninfected cells, the RANTES promoter had low basal activity and vIRF-1 slightly decreased luciferase activity (Figure 7b ). Sendai virus infection activated the RANTES promoter activity up to 70-fold, while coexpression of full length vIRF-1 or CBP3 reduced activity 10-fold and ®vefold respectively (Figure 7b) . Cotransfection of the various vIRF-1 deletions had essentially no eect on virus-induced RANTES promoter activity (Figure 7b) . Coexpression of the constitutively active form of IRF-3 [IRF-3(5D)] activated the RANTES promoter up to 150-fold and again expression of vIRF-1 reduced the IRF-3(5D)-mediated transactivation more than 15-fold ( Figure  7b ). The C-terminal fragment of CBP (aa 1992 ± 2441) was also able to interfere with IRF-3(5D) mediated transactivation and reduced the level of activity about threefold (Figure 7b) . Again, the truncated forms of vIRF-1 had essentially no eect on RANTES promoter induction by IRF-3(5D) (Figure 7b ). Similar results were obtained when the repression potential of full length and truncated vIRF-1 was analysed using the IFNA1 promoter (data not shown).
To test whether the increasing doses of CBP can reverse the inhibition by v-IRF-1, a transient expression assay was performed using the RANTES promoter construct together with the increasing amounts of CBP expression plasmid. As shown previously, in uninfected cells, the RANTES promoter had a low basal activity that was slightly inhibited by vIRF-1 (Figure 8 ). The expression of CBP did not aect the basal RANTES promoter activity but was able to reduce the virus-mediated activation of RANTES promoter about 2.5-fold (Figure 8 ). In cells (Figure 8 ). Cotransfection of CBP was also able to reverse the inhibition of IRF-3(5D)-mediated activation of RANTES promoter by v-IRF-1 (from 10-fold to ®vefold; Figure 8) . Together these results demonstrate that vIRF-1 repressed IRF-3-mediated transactivation through inhibition of IRF-3-CBP/p300 interaction and that full length vIRF-1 was required for this repressive function.
Discussion
In this study, we sought to characterize the molecular mechanisms by which the HHV-8 encoded homolog vIRF-1 interferes with the induction of the immediate early IFN response to virus infection. Previous studies had demonstrated that vIRF-1 was able to downregulate the IFN-stimulated transcriptional activity of various ISG containing promoters (Burysek et al., 1999; Gao et al., 1997; Li et al., 1998; Zimring et al., 1998) . We now demonstrate that vIRF-1 acts at an early step in gene activation to eciently downregulate virus-stimulated transcription of interferon B, CC chemokine RANTES and CXC chemokine IP-10 genes. We further show that although vIRF-1 interacts weakly with both IRF-3 and IRF-7, vIRF-1 speci®cally blocks the transactivation activity of IRF-3 but not IRF-7. Since vIRF-1 only weakly associated with active IRF-3 and did not block the dimerization or DNA binding activity of the constitutively active form of IRF-3, we determined that vIRF-1 interferes with the interaction between IRF-3 and the CBP/P300 coactivators. Our data indicates that full length vIRF-1 but not the N-or the C-terminal truncated forms of vIRF-1 eciently interferes with the recruitment of CBP/p300 co-activators by IRF-3. Together these data indicate that inhibition of cytokine/chemokine gene activation by vIRF-1 may be important to the early events leading to HHV-8 induced lymphoma.
Transcriptional repressors may function by one of several mechanisms: (1) displacement of activators from their DNA binding sites; (2) masking of transcriptional activation domains; (3) interference with the assembly of the basal transcription machinery; or (4) recruitment of multiprotein complexes with chromatin modifying activities to speci®c sites on DNA (Maldonado et al., 1999; Tyler and Kadonaga, 1999) . Since vIRF-1 appears to lack signi®cant DNA binding activity, it is unlikely to function by a competition or displacement mechanism. Similarly, our experiments indicate that vIRF-1 only weakly associates with IRF-3 and thus is probably unable to mask the C-terminal transactivation domain of IRF-3; based on the presented data, it also appears that vIRF-1 does not function by blocking IRF dimerization. Our experiments rather suggest that vIRF-1 prevents the recruitment of CBP to transcriptionally active promoters, based on data showing that in the presence of vIRF-1, IRF-3 is able to bind DNA in vitro, but does not form a high molecular weight complex with CBP ( Figure 6 ). In contrast, vIRF-1 is able to physically associate with CBP, via the C-terminal CBP3 domain, the same region that contacts IRF-3. Association between CBP and vIRF-1 would thus interfere with the assembly of the basal transcription machinery. One prediction of this observation is that vIRF-1 may also interfere with the recruitment of CBP/p300 to other transcriptional complexes that recruit CBP via Cterminal interaction. The fact that IRF-7 mediated activation is not blocked by vIRF-1 is consistent with this interpretation since IRF-7 does not associate with CBP/p300 .
Within the IRF family, the best characterized repressor of IFN activation is IRF-2 which has been shown to antagonize the transactivating eects of IRF-1, in part by binding to the IRF-E recognition site and competing with IRF-1 for DNA complex formation (Nguyen et al., 1995) . A recent study examined the mechanism of IRF-2 mediated repression of the IFNb enhanceosome and revealed that IRF-2 possesses a Cterminal repression domain which functions by inhibiting recruitment of the CBP/p300 coactivator (Senger et al., 2000) . Using in vitro transcription analysis, the inhibitory action of IRF-2 functioned during the early steps of formation of the pre-initiation complex (PIC) by preventing recruitment of CBP, resulting in the formation of non-productive PICs. Chromatin immunoprecipitation experiments also revealed that under Figure 8 The eect of CBP on the vIRF-1-mediated repression. 293 HEK cells were transfected with pRLTK control plasmid, RANTES-pGL3 reporter plasmid, the control plasmids CMVBL, pcDNA3 (C), and the expression plasmids encoding IRF-3(5D) or CBP (Ha-CBP/pcDNA3.1) as indicated. At 8 h post transfection, cells were infected with Sendai virus for 16 h or left uninfected as indicated. Luciferase activity was analysed at 24 h post-transfection by the Dual-Luciferase Reporter assay as described by the manufacturer (Promega). Relative luciferase activity was measured as fold activation (relative to the basal level of reporter gene in the presence of CMVBL vector after normalization with cotransfected RLU activity); values are mean+SD for three experiments physiological conditions of virus infection, IRF-2 incorporated into IFN-b enhanceosomes and prevented a subset of assembled enhanceosomes from recruiting CBP. Curiously, the repression domain of IRF-2 does not interact with the transactivator proteins or with CBP. It is suggested that the C-terminal repression domain of IRF-2 which is rich in basic amino acids may build a positively charged microenvironment that repels CBP in the absence of any detectable repression domainCBP interaction (Senger et al., 2000) .
The CBP/p300 transcriptional coactivators are important regulators of many cellular processes and have tumor suppressing activity (Kung et al., 2000; Oike et al., 1999; Yao et al., 1998) . CBP and p300 proteins interact with a variety of activators including CREB, cMyb, c-Jun, MyoD, P53, STATs, NF-kB and nuclear hormone receptors (reviewed in Shikama et al., 1997; Suzuki et al., 1999) . In addition to interaction with transcriptional activators, CBP/p300 possesses intrinsic histone acetyltranferase activity and interacts with the basal transcription factors, TATA binding protein (TBP) and TFIIB. A growing body of biochemical and genetic evidence also demonstrates that CBP/p300 has tumor suppressive activity. As regulators of cell cycle and tumorigenesis, CBP and p300 are targets for viral oncoproteins such as adenovirus E1a, SV40 large T antigen, HTLV-1 Tax, and tumor suppressor p53 (Shikama et al., 1997; Suzuki et al., 1999) which exert their transforming phenotype in part by neutralizing CBP/p300 function. Based on the data presented in this and previous studies I ( Burysek et al., 1999; Jayachandra et al., 1999) , HHV-8 encoded vIRF-1 can likewise be considered an oncogene with the capacity to ablate CBP/p300 tumor suppressor activity. In fact, recent studies have demonstrated that vIRF-1 directly interacts with p300, displaces p300/CBP-associated factor from p300 complexes and inhibits p300 histone acetyltransferase activity (Li et al., 2000) .
It has been demonstrated that vIRF-1, as well as EBNA1 and E1A, not only prevented interferonmediated activation of interferon-stimulated genes but also activated MYC protooncogene (Jayachandra et al., 1999) . vIRF-1, in association with an unidenti®ed cellular factor, activates MYC transcription through an ISRE sequence called the plasmacytoma repressor factor (PRF) element located in the upstream of MYC promoter. Jayachandra et al. (1999) also demonstrated that vIRF-1 associated with full-length CBP and the two proteins synergistically activated MYC transcription. Interestingly, p300 and P/CAF suppressed vIRF-1-mediated activation of MYC promoter (Jayachandra et al., 1999) . Since the expression of a dominant-negative cMYC inhibited colony formation and reduced the doubling time of vIRF-1 expressing cells, it was suggested that cMYC is required for cell transformation and MYC induction is downstream from vIRF-1 in the transformation pathway (Jayachandra et al., 1999) . Both in vivo coimmunoprecipitation and in vitro GST pull-down studies indicated that vIRF-1 interacted with p300 (Burysek et al., 1999; Jayachandra et al., 1999) .
However, the interaction domain of p300 was mapped to dierent regions: to the N-terminal domain of p300 by Jayachandra et al. (1999) and to the C-terminal domain by Burysek et al. (1999) . In this study, we demonstrate that vIRF-1 associates with the Cterminal region of CBP coactivator.
IRF-3 is targeted by several dierent classes of viruses or products ± paramyxoviruses, herpesviruses, reovirus and double stranded RNA ± implicating it as the major activation pathway for primary IFN gene expression (Mamane et al., 1999) . In this study we demonstrate that vIRF-1 eciently inhibited IRF-3-mediated transactivation by competing for CBP/p300 co-activator recruitment. Another viral product, the E6 protein from human papillomavirus 16 (HPV16), also interferes with IRF-3 mediated activation of IFN-b gene expression in response to Sendai virus infection . This eect was mediated by direct binding between E6 and IRF-3, although E6 does not appear to target IRF-3 for ubiquitination and subsequent proteasome mediated degradation as observed for the tumor suppressor p53 . These two mechanisms of inhibition of IRF-3 activity by viral proteins reveal distinct means by which viruses can interfere with the early stages of the IFN antiviral response.
Recent studies from this laboratory have demonstrated that IRF-3 also contributes to virus-induced apoptosis (Heylbroeck et al., 2000) . The constitutively active form of IRF-3, IRF-3 (5D), was shown to induce apoptosis in human embryonic kidney 293 and Jurkat T cells, while wtIRF-3 on its own, had no eect. Viral infection of cells overexpressing wtIRF-3 enhanced the number of cells undergoing apoptosis by 2 ± 3-fold, depending on the cell type. A dominant negative form of IRF-3, IRF-3DN, interfered with virus induced apoptosis in 293 cells, thus demonstrating that activation of IRF-3 can initiate apoptotic signaling. Hence, inhibition of the pro-apoptotic activites of IRF-3 may also be important for the establishment of transforming infection by oncogenic viruses such as HHV8.
Materials and methods
Plasmid constructions and mutagenesis
The wildtype and mutated forms of IRF-3, IRF-7, IRF-1 and CBP expressing plasmids were described previously (Lin et al., 1994 (Lin et al., , 1999b . The HA-CBP/pcDNA3.1 expressing plasmid was provided by Xiangjiao Yang. Flagtagged vIRF-1 expression plasmids were prepared by cloning the vIRF-1 cDNA (PCR ampli®ed from myc-vIRF-1, a gift from Dr Jung) into the pFlag-CMV-2 (pFlag-IRF-7) vector. RANTES/pGL3, IFNB/pGL3, IFNA1/pGL3 and pRLTK reporter plasmids were described previously .
Cell culture, transfections and luciferase assays
All transfections for Luciferase assay were carried out in human embryonic kidney 293 cells grown in aMEM media (Gibco ± BRL) supplemented with 10% fetal bovine serum, glutamine and antibiotics. Subcon¯uent cells were transfected with 50 ng of pRLTK reporter (Renilla luciferase for internal control), 100 ng of pGL-3 reporter (®re¯y luciferase, experimental reporter) and 200 ng of expression plasmids by calcium phosphate coprecipitation method. The reporter plasmids were: RANTES pGL-3, IFNB pGL3, and IFNA1 pGL-3 reporter genes; the transfection procedures were previously described (Lin et al., 1996) . At 24 h after transfections, the reporter gene activities were measured by Dual-Luciferase Reporter Assay, according to manufacturers' instructions (Promega).
Immunoprecipitation and immunoblot analysis of protein-protein interactions
293 cells were cotransfected with expression plasmids as indicated. Whole cell extracts (200 ± 500g) were prepared from co-transfected cells and the extracts was incubated with 2 ml anti-myc antibody 9E10 or 0.5 mg anti-CBP antibody A22, anti-P300 antibody N15 cross-linked to 30 ml of protein A-Sepharose beads for 1 h at 48C (Lin et al., 1999b) . Precipitates were washed ®ve times with lysis buer, eluted by boiling the beads 3 min in 16 SDS sample buer. Eluted proteins or 5% input whole cell extracts were subjected to SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) in a 10% polyacrylamide gel. After electrophoresis, proteins were transferred to Hybond transfer membrane (Amersham) in a buer containing 30 mM Tris, 200 mM glycine and 20% methanol for 1 h. The membrane was blocked by incubation in phosphate-buered saline (PBS containing 5% dried milk for 1 h and then probed with anti-IRF-3, anti-Flag, anti-CBP, anti-P300 or anti-myc antibody (1 : 1000 ± 1 : 3000). Immunocomplexes were detected by using a chemiluminescence-based system (ECL).
Electromobility shift assay
Whole cell extracts were prepared 40 h after transfection with 5 mg of expression plasmids, as indicated in individual experiments. Cells were washed in phosphate-buered saline and lysed in 10 mM Tris-Cl pH 8.0, 60 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml pepstatin, 10 mg/ml aprotinin, 0.5 mg/ml chymostatin and 0.25 mM microcystin. Equivalent amounts of whole cell extract (20 mg) were assayed for IRF-3 or IRF-7 binding in gel shift analysis using 32 P-labelled doublestranded oligonucleotide corresponding to the PRDI-PRDIII region of IFNB promoter: 5'-GAAAACTGAAAGGGA-GAAGTGAAAGTG-3'. Complexes were formed by incubating probe with 20 mg of each whole cell extracts in the presence or absence of the indicated antibodies. The binding mixture (20 ml) contained 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM NaCl, 2 mM DTT, 5% glycerol, 0.5% NP40, 10 mg/ml of BSA, 62.5 mg/ml of poly dI-dC was added to reduce non-speci®c binding. To demonstrate the speci®city of protein-DNA complex formation, 500-fold molar excess of unlabeled wildtype or mutated oligonucleotide corresponding to the ISRE region of the RANTES promoter (wt: 5'-CTATTTCAGTTTTCTTTTCCGTTTTGTG-3', mut: 5'-CTATTTCAGTAAACTAAACCGTTTTGTG-3') was added to the cell extract before adding labeled probe, or preincubated with anti-CBP antibody A-22 and anti-IRF-3 antibody (Santa Cruz Biotechnology Inc.). After 20 min incubation with probe, extracts were loaded on a 5% polyacrylamide gel (60 : 1 crosslink) prepared in 0.56TBE. After running at 200 ± 250 V for 2 h, the gel was dried and exposed to a Kodak ®lm at 7708C overnight.
Generation of pcDNA3 and vIRF-1 cell lines
Plasmid pcDNA3 and myc-vIRF-1 was introduced into human 293 cells by the calcium phosphate method. Cells were selected beginning at 48 h for a period of approximately 2 weeks in aMEM containing 10% heatinactivated calf serum, glutamine, antibiotics, and 400 mg/ml G418 (Life Technologies, Inc.) and a polyclonal population consisting of approximately 200 individual clones.
Ribonuclease protection analysis and ELISAs
For ribonuclease protection assay, cells were either left untreated or infected with Sendai virus (80 HAU/ml) for 4, 8 or 12 h. Total RNA was prepared from the cell pellets using the Qiagen 2 RNeasy Kit 2 . Total RNA (5 mg) was subjected to RNase Protection Assay using hCK-5 chemokine template of RiboQuant 2 multi-probe RPA kit, following the manufacturer's instructions (Pharmingen, San Diego, CA USA).
